NewAmsterdam Pharma (NASDAQ:NAMS) Receives $43.33 Consensus Price Target from Analysts

NewAmsterdam Pharma (NASDAQ:NAMS) has earned an average recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $43.33.

A number of equities research analysts have weighed in on the company. UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a report on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Needham & Company LLC dropped their price objective on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. Royal Bank of Canada reissued an “outperform” rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Finally, Scotiabank upped their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 27th.

Insider Activity

In related news, major shareholder Nap B.V. Forgrowth sold 100,728 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $26.10, for a total value of $2,629,000.80. Following the completion of the sale, the insider now owns 10,908,502 shares of the company’s stock, valued at $284,711,902.20. This trade represents a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of the company’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the transaction, the chief accounting officer now directly owns 15,000 shares in the company, valued at approximately $305,550. This represents a 90.91 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 388,916 shares of company stock worth $9,231,268. 19.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in NAMS. GF Fund Management CO. LTD. bought a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $50,000. National Bank of Canada FI bought a new stake in shares of NewAmsterdam Pharma during the 4th quarter valued at $51,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of NewAmsterdam Pharma during the 4th quarter valued at $80,000. Quarry LP lifted its stake in shares of NewAmsterdam Pharma by 2,469.2% in the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after purchasing an additional 6,247 shares during the period. Finally, Barclays PLC boosted its position in shares of NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after purchasing an additional 7,199 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Trading Up 0.9 %

NAMS opened at $23.58 on Tuesday. The stock’s 50 day simple moving average is $22.00 and its 200-day simple moving average is $20.67. The stock has a market cap of $2.59 billion, a PE ratio of -9.07 and a beta of -0.04. NewAmsterdam Pharma has a 1 year low of $15.19 and a 1 year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to analysts’ expectations of $3.30 million. Equities analysts forecast that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.